LM-030

Star0

DB18283InvestigationalSmall molecule

LM-030: Overview.

Formula / weight: C₄₆H₇₂N₈O₁₂ · 929.126 g/mol (avg)
Also known as: (S)-2-ISOBUTYRYLAMINO-PENTANEDIOIC ACID 5-AMIDE 1-{[(2S,5S,8S,11R,12S,15S,18S,21R)-2,8-BIS-((S)-SEC-BUTYL)-21-HYDROXY-5-(4-HYDROXY-BENZYL)-15-ISOBUTYL-4,11-DIMETHYL-3,6,9,13,16,22-HEXAOXO-10-OXA-1,4,7,14,17-PENTAAZA-BICYCLO[16.3.1]DOCOS-12-YL]-AMIDE · L-ISOLEUCINE, N2-(2-METHYL-1-OXOPROPYL)-L-GLUTAMINYL-L-THREONYL-L-LEUCYL-(.ALPHA.S,3S,6R)-3-AMINO-6-HYDROXY-.ALPHA.-((1S)-1-METHYLPROPYL)-2-OXO-1-PIPERIDINEACETYL-N-METHYL-L-TYROSYL-, (6->2)-LACTONE
Code names: BPR-277 · LM-030

Resolves to

Compound

UNII31I6DBK5RWCAS1122484-55-2

Structure

InChIKeyQZEXRDYEZBKQHM-TULYSKAASA-NSMILES

[H][C@@]12CC[C@@H](O)N([C@@H]([C@@H](C)CC)C(=O)N(C)[C@@H](CC3=CC=C(O)C=C3)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N1)C2=O

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of LM-030, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account